The award comes as Singapore becomes what the announcement describes as a “super-aged” society, with people aged 65 and older accounting for one-fifth of the population. This proportion is estimated to expand to one-quarter by 2030. Against this demographic shift, Straughan and her team will examine how neighbourhoods, public spaces and patterns of informal interaction may help residents sustain social connections and health-promoting routines as they age.

The work will focus on the combined influence of the built environment, community interaction and behavioural “nudges,” rather than relying only on restrictions such as bans on sugary drinks. One central concept is the sociological “Third Place,” defined in the announcement as a physical setting that encourages informal social interaction outside the home and workplace, such as a café. Straughan said infrastructure can serve purposes beyond aesthetics by creating places intentionally designed to bring people together.

Hawker centres, for example, could become community kitchens, with programmes and social events designed to attract people and embed messages about health and well-being in everyday settings. The research team also plans to work with relevant government agencies on a project involving such spaces, although the release does not identify a selected site or policy. The team will analyse how social settings and the built environment can “nudge” people toward willingly adopting behaviours that support physical activity, mobility and social participation.

She described the aim as developing spaces alive with programmes, events and relationships, where health messaging could be embedded naturally. Because many people would encounter those messages collectively, she said, such settings could begin to change community norms. These are the programme’s proposed mechanisms; the announcement does not yet establish that they will improve health outcomes.

Straughan offered an everyday illustration of the idea from a morning visit to a condominium gym. A neighbour had brought in an enthusiastic personal trainer, turning the normally quiet room into a loud, motivational space. The sociologist initially found the noise irritating but chose to respond with friendship and serenity, reasoning that neighbours could not complain about one another.

The episode illustrates her argument that social ties can break down barriers, lessen hostility and encourage healthier lifestyles. It was an anecdote used to motivate the research, not evidence that the proposed programme works, and no controlled comparison was described. A major analytical resource for the programme is the Singapore Life Panel, a longitudinal survey maintained by ROSA since 2015.

The announcement calls it the world’s largest high-frequency longitudinal survey on ageing and reports that it produces about 7,500 responses each month from Singapore residents aged 50 to 80. Its responses are self-reported, meaning that the data reflect participants’ own assessments and are subjective rather than direct clinical measurements. To enhance the panel’s analytical potential, ROSA plans to link Singapore Life Panel data with the Ministry of Health’s TRUST platform.

TRUST collates anonymised health-related research and objective real-world data and is accessible only to vetted researchers. The proposal describes the combined dataset as nationally significant and suitable for holistic, cross-cohort and policy-relevant research on ageing. Data linkage is presented as a core component of the programme, but the announcement provides no results from the linked dataset and does not specify which measures, records or participant groups will be included in the analysis.

The new Academic Research Fund Tier 3 award represents a second round of funding for ROSA over the next five years. Straughan nevertheless emphasised that maintaining the Singapore Life Panel depends on continuing university support, particularly for personnel. She said the core team is responsible for maintaining the panel and cultivating the contacts on which its longitudinal work depends.

The funding announcement did not disclose the monetary value of the award or explain how much university staffing support would accompany it, leaving the operating resources for the five-year programme unspecified. The project also reflects Straughan’s view that ageing should be treated as a productive stage of life rather than a period in which people are “just waiting to die.” She said community participation can help seniors retain talent and transform their experience into social assets for the wider community. This social dimension matters, she argued, because household sizes are shrinking and elder care can no longer be the sole responsibility of immediate family.

Rather than confining mutual support to formal family relationships, she wants to explore how lively neighbourhoods and high social capital may broaden the networks through which residents look after one another, while the State remains responsible for those who are extremely poor and require direct intervention. Taken together, the five-year programme will test whether the places in which people live, move and meet can be deliberately shaped to support well-being during ageing. Its proposed pathway links urban design and Third Places with community participation, social norms and health-related behaviour, while the Singapore Life Panel and linked health data provide the empirical foundation.

Whether environmental and social nudges improve mobility, physical activity or other health outcomes remains to be established. For now, the award funds a research effort to measure and evaluate relationships between neighbourhood conditions, social participation and successful ageing in Singapore.

Subject of Research: Research on urban design and social environments supporting older adults’ well-being in Singapore

Article Title: Nudging Super-aged SG towards fruitful longevity

Article References: Nudging Super-aged SG towards fruitful longevity. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: healthy ageing, older adults, urban design, social environments, community participation, behavioural nudges, Singapore, longitudinal survey, health data linkage, social connection, Nudging, Super-aged

The work was led by the National Cancer Centre Singapore in collaboration with the A*STAR Institute of Molecular and Cell Biology, Singapore General Hospital and the Yong Loo Lin School of Medicine at the National University of Singapore. The peer-reviewed paper, “Identification of novel paracrine therapeutic targets in peritoneal metastases through integrative proteotranscriptomic analysis of ascites,” was published in Molecular Cancer on 11 September 2026.

Peritoneal metastases occur when cancers originating in abdominal organs spread to the peritoneum, the lining of the abdominal cavity. The source identifies gastric, colorectal and ovarian cancers as common primary sources, giving reported ranges of 20–25%, 20–45% and 60–75%, respectively. The condition is often diagnosed at Stage IV, has a median survival of under nine months and is frequently managed with palliative intent. Surgery, regionalised chemotherapy and systemic chemotherapy have limited curative ability.

Many patients with peritoneal metastases develop ascites, an accumulation of fluid in the abdomen. The 2026 study investigated the molecular pathways in this fluid that may support tumour development. It built on an earlier 2022 National Cancer Centre Singapore study, which had established that targeting ascites could inhibit tumour growth; the new analysis sought to characterise biological pathways and therapeutic vulnerabilities more comprehensively.

Using multiomic profiling, the team analysed proteins and biological pathways in a 397-sample ascites dataset spanning 21 primary cancer types. The collection is described by the researchers as one of the world’s largest ascites datasets. The analysis identified several paracrine factors implicated in tumour development, with PAI-1 and S100A10 emerging as key drivers in the ascites microenvironment.

The team selected PAI-1 as a therapeutic target because of its clinical and prognostic relevance in cancer progression. Instead of developing a conventional monoclonal antibody, the researchers created E8, a smaller antibody-derived drug known as a nanobody. The source notes that nanobodies have low immunogenicity and a reduced toxicity risk, and that these properties could support better tolerability than some existing treatments, although this was not established in patients in the reported experiments.

Investigators assessed E8 in three preclinical systems: in vitro cell assays, in vivo mouse models and ex vivo human tissue explants in which tumour tissue was grown in patients’ ascites. Across all three systems, E8 suppressed tumour growth with minimal toxicity. These findings support further investigation of E8 as a treatment directed at the ascites microenvironment, but the experiments do not demonstrate clinical efficacy, safety or patient benefit.

Associate Professor Johnny Ong, the study’s senior author and head of the Department of Sarcoma, Peritoneal and Rare Tumours at Singapore General Hospital and NCCS, said the work creates the possibility of a new class of treatments for peritoneal metastases that targets the tumour microenvironment through ascites rather than tumour cells directly. He said the pathway may have implications for cancers that result in ascites, including ovarian, gastrointestinal, liver, breast and lung cancers.

Dr Joe Yeong, co-author and principal investigator at A*STAR’s Institute of Molecular and Cell Biology, described E8 as a therapeutic candidate with potential to improve outcomes for patients who have limited treatment options. Professor Jimmy So of NUS Medicine said the research could help pave the way for effective therapy for peritoneal metastasis. These statements describe translational potential; the study itself was experimental and preclinical.

The researchers are working to advance E8 toward clinical-grade development and a first-in-human clinical trial. In parallel, they are developing a companion biomarker test to identify patients with elevated PAI-1 levels who may be most likely to benefit from E8. These efforts are part of the Melyorax Initiative, a newly established biologics research programme led by Ong, with E8 as its lead asset. Whether the suppression observed in laboratory and animal models will translate into clinical benefit remains to be established.

Subject of Research: Preclinical identification of ascites targets and testing of the E8 nanobody in peritoneal metastases

Article Title: SG research team develops novel nanobody targeting tumor-fueling fluid to treat late-stage cancer of the abdominal lining

Article References: SG research team develops novel nanobody targeting tumor-fueling fluid to treat late-stage cancer of the abdominal lining. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: peritoneal metastases, ascites, PAI-1, S100A10, E8 nanobody, tumour microenvironment, preclinical research, cancer therapeutics, Singapore, research, team, develops

According to the study abstract, in-hospital mortality was 43.0% among patients with S. maltophilia, compared with 29.5% to 31.3% for the other two pathogens; the difference was statistically significant at p < 0.001. One-year mortality was also higher for S. maltophilia, at 45.7% versus 34.9% to 36.2% for P. aeruginosa and A. baumannii (p = 0.049). The authors also reported substantially greater years of potential life lost for S. maltophilia bacteremia, with a geometric mean of 15.4 years (p < 0.001).

Patient characteristics differed among the three groups. Patients with S. maltophilia bacteremia had a mean age of 61.5 years and higher recorded rates of central venous catheter use, reported in 78.1% of cases, and neutropenia, reported in 25.2%. Acquired resistance was less prevalent in the S. maltophilia group, at 27.2%, than in A. baumannii, at 52.1%, or P. aeruginosa, at 34.2% (p < 0.001). The abstract defines acquired resistance for S. maltophilia as non-susceptibility to levofloxacin, cotrimoxazole or minocycline, while for the other pathogens it refers to non-susceptibility to one or more agents in standard antipseudomonal or antimicrobial categories, using Clinical and Laboratory Standards Institute breakpoints.

Appropriate empirical therapy was reported for 67.5% of patients with S. maltophilia, 62.6% of those with A. baumannii, and 85.5% of those with P. aeruginosa (p < 0.001). Multivariable logistic regression estimated that appropriate empirical therapy was associated with lower mortality at all assessed timepoints, with the strongest association at 30 days (adjusted odds ratio 0.42, p = 0.002). The authors stated that the lower rate of appropriate empirical therapy for S. maltophilia was consistent with a contribution from delayed effective therapy, but the observational design does not establish that treatment timing caused the mortality differences. As a single-center retrospective study summarized here from its abstract, the findings are limited in their ability to separate organism-specific effects from differences in patient characteristics, treatment selection and other clinical factors. The authors stated that prospective studies are required to determine whether earlier organism identification or risk-stratified empirical treatment improves clinical outcomes.

Subject of Research: Comparative clinical outcomes of three non-fermenting Gram-negative pathogens in adult bacteremia

Article Title: Comparative analysis of clinical outcomes in non-fermenting gram-negative bloodstream infections: Stenotrophomonas maltophilia versus Pseudomonas aeruginosa and Acinetobacter baumannii in Asian Tertiary Care

Article References: Yang, Y., Lai, D. C. M., Foo, M. Z. Q., Low, C. T., Tan, Y. E., Aung, M. K., Aung, M. O., Arora, S., Chan, D. Y. W., Wee, I. L. E., Sim, J. X. Y., Sridharan, S., Chlebicki, M. P., & Venkatachalam, I. (2026). Comparative analysis of clinical outcomes in non-fermenting gram-negative bloodstream infections: Stenotrophomonas maltophilia versus Pseudomonas aeruginosa and Acinetobacter baumannii in Asian Tertiary Care. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14658-9

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14658-9

Keywords: S. maltophilia, P. aeruginosa, A. baumannii, bacteremia, bloodstream infections, mortality, empirical therapy, antimicrobial resistance, retrospective cohort, Singapore, Comparative, analysis

Researchers analysed data from adults aged 21–69 years who had a low 10-year cardiovascular risk according to the 2023 Singapore modified Framingham risk score and were not taking antihypertensives. Participants were recruited from public or clinic settings through convenience sampling. Following consent, they completed structured questionnaires, clinical examinations and investigations that included office blood pressure measurement and 24-hour ambulatory blood pressure monitoring, using validated instruments.

The participant group had a mean age of 45.5 years, with a standard deviation of 11.8 years. Women represented 51.6% of the cohort, and 91.2% of participants were of Chinese ethnicity. Normal body mass index and waist circumference were observed in 47.0% and 60.7%, respectively. Most participants were nonsmokers, at 90.9%, and engaged in physical activity, at 81.3%.

Hypertension prevalence was 25.5% based on office blood pressure and 22.7% based on 24-hour ambulatory blood pressure monitoring. The abstract also reports that 38.5% of participants were diagnosed by any ambulatory blood pressure target. Daytime hypertension was observed in 17.4%, masked hypertension in 19.4%, and a non-dipping blood pressure pattern in 59.7% of the cohort. These findings are observations from a cross-sectional convenience sample rather than measures of change over time or evidence of future cardiovascular events. The predominantly Chinese sample and recruitment from public or clinic settings also limit how broadly the results can be generalised. Although the study aimed to examine associated factors, the supplied abstract does not present those analyses. The authors state that longitudinal follow-up could assess the prognostic significance of the phenotypes and their implications for cardiovascular risk stratification.

Subject of Research: Prevalence of hypertension phenotypes among low-risk adults in urban Singapore

Article Title: Prevalence of hypertension phenotypes in an urban population with low cardiovascular risk in Singapore: a cross-sectional study

Article References: Moosa, A. S., Chaterji, S., Ng, D. X., Kumar, B., Kong, S. C., Huang, W., Yap, J., Yeo, K. K., & Ng, C. J. (2026). Prevalence of hypertension phenotypes in an urban population with low cardiovascular risk in Singapore: a cross-sectional study. BMC Public Health. https://doi.org/10.1186/s12889-026-29454-y

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29454-y

Keywords: hypertension, ambulatory blood pressure monitoring, nocturnal hypertension, masked hypertension, white-coat hypertension, non-dipping blood pressure, cardiovascular risk, Singapore, cross-sectional study, Prevalence, phenotypes, urban

The reference was developed by a working group under the Biomedical and Health Standards Committee of the Singapore Standards Council. Enterprise Singapore administers the council, while the Duke-NUS Centre of Regulatory Excellence–Standards Development Organisation supported the work. The group included representatives from public healthcare institutions, ethics committees, industry and regulatory bodies. TR 151 explains how ISO 14155:2026, the international standard for good clinical practice in medical device investigations, should be applied when planning and reviewing device studies in Singapore.

Singapore’s existing clinical-trial guidance was largely designed with medicines in mind and offered limited direction on device-specific considerations, according to the announcement. As a result, applications for medical device studies could vary widely in content and depth, leaving innovators without a shared understanding of what ethics committees expected. Inconsistent applications could trigger repeated requests for clarification, imposing particular burdens on start-ups and small and medium-sized enterprises with limited regulatory resources.

TR 151 seeks to address that variability by linking the evidence expected at ethics review to two features of an investigation: the device’s risk class and its stage of development. The stated aim is not to impose identical requirements on every study, but to establish a proportional approach. Study teams can use the reference while planning their evidence, while sponsors and manufacturers can prepare more complete applications. Reviewers gain an internationally informed framework against which to assess submissions.

Fiona Loke, Director of the Medical Technology Office at SingHealth and the working group convener, said the participants sought international best practices and drew on industry, public and private healthcare providers, and experts in regulation and ethics review. “Innovators preparing to undergo an ethics review for their medical device study can now prepare their submissions using a common reference, based on their device’s risk class and study stage,” she said.

Professor John Lim, Executive Director of the Centre of Regulatory Excellence at Duke-NUS Medical School, said the reference consolidates what regulators, ethics committees, clinicians and industry had learned about conducting device studies well. He said TR 151 is applicable from the earliest planning stages and is intended to support trust in clinical evidence generated in Singapore and help innovators bring safe, effective devices to patients with greater confidence.

Lee Suen Ming, Chair of the Biomedical and Health Standards Committee, encouraged the healthcare community to adopt the reference. “Singapore’s medtech ecosystem is producing more homegrown devices that must be tested in patients for the first time. TR 151 provides hospitals, ethics committees and companies with common guidance for conducting these investigations,” he said. He said broader adoption could improve the quality and consistency of submissions while safeguarding participant safety.

The initiative is aimed specifically at investigational medical devices, defined in the announcement as devices that remain experimental for their intended use. It is a procedural standard for preparing and reviewing clinical investigations rather than evidence that any particular device is safe or effective, and the announcement does not report results from patient studies. Its anticipated effects are more predictable ethics review, clearer planning for developers and sponsors, and a more consistent basis for assessing submissions. Both TR 151:2026 and the Singapore adoption of ISO 14155:2026 were made available for purchase through the Singapore Standards eShop.

Subject of Research: A national technical reference for clinical investigations of investigational medical devices in Singapore

Article Title: Singapore launches national reference to guide clinical investigations of medical devices

Article References: Singapore launches national reference to guide clinical investigations of medical devices. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: medical devices, clinical investigations, ethics review, regulatory standards, ISO 14155, Singapore, risk management, research ethics, healthcare innovation, launches, national, reference

The core of the partnership lies in pairing two complementary capabilities. ASTAR brings scientific expertise and therapeutic development infrastructure built over years of public investment in biomedical research, while HistoIndex contributes a proprietary imaging platform that applies artificial intelligence to produce fully quantitative tissue analysis. The stated goal is to provide objective, sensitive and accurate measures of fibrosis and of treatment response, so that researchers evaluating ASTAR’s pipeline of therapeutic candidates can make better-informed decisions about which compounds merit further advancement. In early-stage drug development, where animal models and human tissue samples are the primary evidence available, the quality of tissue measurement often determines whether a promising mechanism is correctly recognized or prematurely dismissed.

Fibrosis, the excessive accumulation of fibrous connective tissue that follows chronic injury or inflammation, poses a persistent measurement problem for drug developers. Scarring can affect virtually any organ, from the liver and lungs to the heart, kidneys and skin, and in oncology the dense, stiffened stroma that surrounds many tumors, known as cancer-associated fibrosis, can physically block drug delivery and create a microenvironment that supports tumor growth and immune evasion. Determining whether an experimental therapy can prevent, halt or reverse these processes requires detecting subtle changes in collagen deposition and tissue architecture, changes that conventional assessment methods struggle to capture reliably.

Traditional histopathology relies on visual inspection of stained tissue sections, in which pathologists grade fibrosis on ordinal scales. Such scoring is inherently semi-quantitative and subject to inter-observer variability, and it can miss spatial patterns of scarring that carry biological meaning. Quantitative approaches such as second harmonic generation microscopy, which exploits the intrinsic optical properties of collagen fibrils to image them label-free, combined with machine learning analysis, offer a way to convert tissue images into continuous, reproducible numerical readouts. This is the technological space in which HistoIndex operates, and it is precisely the kind of measurement rigor that Dr Ooi highlighted when describing the challenge of early development: understanding whether a candidate can prevent, halt or reverse fibrosis requires accurate and objective measurement of changes in fibrotic tissue, something the collaboration is intended to support more rigorously.

According to A*STAR, the collaboration will help the agency assess these effects more rigorously and make better-informed development decisions, with the ultimate aim of advancing innovations that improve patient outcomes. That framing reflects a wider shift in the pharmaceutical sciences toward quantitative, image-based endpoints in preclinical studies. When fibrosis burden can be tracked as a continuous variable across serial tissue samples, dose-response relationships become clearer, and the difference between a therapy that stabilizes disease and one that genuinely regresses scarring becomes measurable rather than impressionistic. For a public research agency charged with translating laboratory discoveries toward clinical benefit, access to such a platform could materially reduce the attrition rate of early-stage candidates.

The partnership also carries a notable institutional backstory. HistoIndex originated as one of A*STAR’s early medtech spin-offs, and Dr Ho emphasized the symbolic weight of bringing the company’s globally validated and widely adopted technology back to Singapore, where the journey began. In remarks at the signing, he described the collaboration as an opportunity to work with the local research community to identify promising therapies and to advance precision medicine for a broad range of fibrotic diseases across multiple organs. The full-circle character of the arrangement illustrates a model of public research investment that has, in this case, produced a commercial enterprise now reinvesting its capabilities in the national research ecosystem that seeded it.

Beyond the immediate task of evaluating therapeutic candidates, the MoU establishes a broader framework for scientific exchange between the two organizations. The announced areas of potential exploration include biomarker discovery, translational research, joint therapeutic development and commercialization. Each of these extends the value of the underlying imaging capability. Quantitative tissue signatures of fibrosis, for example, can serve as candidate biomarkers that link preclinical findings to clinical measurements, easing the transition of a therapy from animal studies to human trials. Joint development and commercialization pathways, meanwhile, suggest that both parties envision the relationship as a continuing engine for new therapeutic programs rather than a one-off service arrangement.

The announcement arrives amid intensifying global interest in antifibrotic drug development. Fibrotic diseases collectively represent a substantial unmet medical need, with few approved therapies capable of reversing established scarring in most organs, and cancer-associated fibrosis has moved to the forefront of oncology research as investigators pursue strategies to remodel or deplete the tumor stroma to improve drug penetration and immune response. In this context, tools that render fibrosis objectively measurable are not merely laboratory conveniences; they are enablers of clinical progress, because clinical trials for antifibrotic agents are famously long, expensive and prone to failure when endpoints are insensitive to genuine biological change.

Separately from the MoU, HistoIndex stated that it will showcase its digital pathology and AI-based tissue analysis capabilities at this year’s AASLD The Liver Meeting Exhibition in Denver, Colorado, underscoring the company’s continued focus on liver disease, one of the most prominent arenas for fibrosis research given the burden of metabolic dysfunction-associated steatohepatitis and viral hepatitis worldwide. The dual announcement, a domestic research partnership and an international scientific showcase, positions the company at the intersection of academic collaboration and clinical community engagement, both of which feed the validation cycle on which quantitative pathology platforms depend.

For the wider biomedical research community, the A*STAR–HistoIndex agreement offers a case study in how measurement technology and therapeutic development can be deliberately coupled at the earliest stages of the pipeline. Rather than treating tissue analysis as a downstream service procured once a drug candidate exists, the MoU embeds quantitative fibrosis assessment within the evaluation process itself, from preclinical characterization through decisions on candidate advancement. If the collaboration fulfills its stated aims, the result should be a more rigorous and efficient path from laboratory discovery to therapies capable of meaningfully altering the course of fibrotic disease, in Singapore and potentially well beyond it.

Subject of Research: Preclinical evaluation of fibrosis therapies using AI-driven digital pathology through an A*STAR–HistoIndex partnership

Article Title: HistoIndex and A*STAR partner to advance early-stage development of pipeline therapies for fibrotic diseases

Article References: HistoIndex and A*STAR partner to advance early-stage development of pipeline therapies for fibrotic diseases. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: A*STAR, HistoIndex, fibrosis, cancer-associated fibrosis, digital pathology, artificial intelligence, preclinical research, drug development, biomarker discovery, precision medicine, Singapore, tissue analysis

The study took the form of a multi-stakeholder roundtable, a format designed to bring rival professional perspectives into the same room and force them to negotiate priorities rather than talk past each other. The session was audio-recorded, transcribed verbatim and analyzed using reflexive thematic analysis, a qualitative method in which researchers actively acknowledge how their own clinical and cultural backgrounds shape the interpretation of the data. From that process, five distinct themes emerged, and together they sketch a blueprint for how a pluralistic health system, one in which biomedical and traditional medicine coexist, can begin to make integrative oncology a routine, coordinated part of cancer treatment rather than an unregulated parallel track.

The first priority identified by participants was strikingly simple: conversations about integrative oncology therapies need to happen earlier and recur throughout the cancer care trajectory. At present, discussions about herbal medicine or acupuncture, when they happen at all, tend to occur at a single point in treatment, often triggered by a complication rather than by proactive planning. Cancer care is dynamic. Regimens change, symptoms evolve, and a therapy that was harmless during surgery may become risky during chemotherapy. Stakeholders argued that asking about traditional therapy use should become as habitual as asking about allergies or medications, repeated at diagnosis, at each treatment transition and into survivorship, so that risks can be reassessed continuously rather than discovered retrospectively.

The second theme addressed the practical plumbing that would be needed to connect two systems that currently operate largely in isolation. Participants called for shared documentation and bidirectional referral pathways between conventional cancer centers and community practitioners of traditional medicine. In the current arrangement, a patient might see a Traditional Chinese Medicine physician in a charity clinic, an oncologist at a public hospital and a general practitioner in between, with none of them able to see what the others have prescribed. The stakeholders envisioned a system in which a community practitioner who identifies a red flag, such as an herb with anticoagulant properties in a patient about to undergo surgery, could escalate the case directly to a specialist, and in which oncologists could refer patients downward to trusted community providers for supportive care. Without this infrastructure, coordination depends entirely on the patient’s memory and willingness to disclose.

The third theme revealed something deeper about how medical decisions are actually made in Singapore’s cultural context. Integrative oncology choices, participants noted, are frequently shaped not by patients alone but by family members and wider community networks. A spouse may insist on a particular herbal tonic; adult children may research supplements online; extended family may offer well-meaning advice rooted in tradition. Western bioethics tends to treat patient autonomy as an individual matter, but in many Asian families, decision-making is relational, distributed across the people who love and care for the patient. The stakeholders concluded that support services must accommodate this reality rather than fight it, engaging families as partners in safety conversations instead of treating their involvement as an obstacle to autonomous choice.

Cost and clinical legitimacy formed the fourth theme, and it exposed a feedback loop with real consequences for equity. Patients were described as reluctant to pay out of pocket for integrative therapies unless they carried some form of oncology endorsement. In a health system where out-of-pocket spending is a significant component of financing, this means that the therapies most likely to be used are those that are cheapest or most visible, not necessarily those with the best evidence. Research from Southeast Asia has documented how complementary medicine costs following a cancer diagnosis can impose substantial financial strain on households in the region. The roundtable participants suggested that real-world outcomes data on integrative oncology uptake within conventional care would be essential for informing any future subsidy mechanisms, because payers and policymakers need evidence of benefit before they will fund a service.

The fifth theme positioned cancer centers themselves as the engines of credibility and training. Participants viewed institutions such as the National Cancer Centre Singapore as instrumental in providing the clinical legitimacy that evidence-informed integrative therapies currently lack, and in building a workforce capable of delivering them. This matters because the field of integrative oncology, as formally defined in a 2017 consensus statement, is not about endorsing everything labeled natural; it is about rigorously evaluating mind-body practices, natural products and lifestyle interventions and integrating those with demonstrated benefit into standard supportive care. International guidelines from the Society for Integrative Oncology and the American Society of Clinical Oncology already recommend specific approaches for managing anxiety, depression, fatigue and pain in cancer patients. The gap identified in Singapore is not a lack of evidence but a lack of institutional machinery to translate that evidence into routine practice.

What makes the Singapore case particularly instructive is the nature of its health system. The country operates a pluralistic model in which Western biomedicine and Traditional Chinese Medicine coexist within a regulated framework, and the government has publicly encouraged the use of evidence-based traditional Chinese medicine alongside Western practice. Traditional Chinese Medicine institutions, including charity organizations such as the Singapore Thong Chai Medical Institution and the Singapore Chung Hwa Medical Institution, both of which were represented among the roundtable participants, serve large patient populations. Meanwhile, national initiatives to transform primary care are creating new expectations for coordinated, longitudinal care across providers. In this environment, the study’s authors argue, the goal should not be to eliminate traditional therapy use but to make pre-existing use safer, more visible and better coordinated.

The safety rationale for this approach is well documented in the international literature. Systematic reviews have consistently found that disclosure of complementary medicine use to medical providers is low worldwide, with many patients believing their doctors would disapprove or that the information is irrelevant. Studies specific to Singapore have reported high rates of complementary and alternative medicine use among adult cancer patients, often self-directed and undisclosed. Pharmacists and oncologists know that certain herbal products can induce or inhibit the cytochrome P450 enzymes that metabolize many chemotherapy agents, potentially altering drug exposure, yet none of this can be managed if the exposure itself is hidden. The roundtable findings suggest that the solution lies less in lecturing patients about disclosure and more in building a system in which disclosure is easy, non-judgmental and clinically rewarded.

The study, which was determined exempt from formal ethical review by the SingHealth Centralized Institutional Review Board and funded without external grants, arrives at a moment when integrative oncology is moving from the margins of cancer medicine toward its mainstream. Global surveys of supportive care providers show growing interest in modalities ranging from acupuncture to mindfulness, and clinical trials in Singapore, such as work evaluating Traditional Chinese Medicine interventions for cancer-related fatigue, are generating local evidence. The roundtable’s conclusions are clear-eyed about what remains undone: real-world data on uptake and outcomes, sustainable financing mechanisms, shared records and trained personnel. But they also carry a message that resonates far beyond Singapore. Wherever patients live in cultures where traditional medicine is embedded, the choice facing health systems is not whether patients will use these therapies, because they already do, but whether the system will meet them where they are and make that use safe.

Subject of Research: Stakeholder priorities for integrating traditional and complementary therapies into cancer care in Singapore's pluralistic health system

Article Title: Stakeholder priorities for advancing integrative oncology across a pluralistic health system: a qualitative study from Singapore

Article References: Ke, Y., Fok, R. W. Y., Ho, S., Tan, R. Y. C., Ramalingam, M. B., Thum, M. C. M., Ng, D. Q., Tan, Y. P., Tan, E. U. T., Chong, W. Q., Yee, C. M., Zheng, H. F., Peh, W. L. W., Ang, S. K., Chay, W. Y., Tan, T. J. Y., Neo, P. S. H., Zhong, L., Chee, C. E., … Deng, G. (2026). Stakeholder priorities for advancing integrative oncology across a pluralistic health system: a qualitative study from Singapore. Supportive Care in Cancer, 34(10), Article 939. https://doi.org/10.1007/s00520-026-11167-y

Image Credits: AI Generated

DOI: 10.1007/s00520-026-11167-y

Keywords: integrative oncology, traditional Chinese medicine, complementary medicine, cancer care, Singapore, patient safety, qualitative research, supportive care, health policy, care coordination, patient disclosure, pluralistic health system

Living kidney donation is one of medicine’s most ethically charged procedures. The donor undergoes major surgery and assumes real physical risk with no direct medical benefit, while the recipient gains freedom from dialysis and, often, years of extended life. Because the stakes are so asymmetric, the entire legitimacy of the practice rests on the donor’s consent being genuinely voluntary and informed. In Singapore, this is enforced through the Human Organ Transplant Act, which requires every living-donor transplant to be reviewed by a national Transplant Ethics Committee, or TEC. Each committee meeting includes a layperson and two doctors uninvolved in transplant medicine, drawn from a national list overseen by the National Organ Transplant Unit. Donors and recipients are interviewed separately, and a rejection by the TEC effectively prevents transplantation anywhere in the country, placing enormous weight on the decisions made before a case even reaches formal review.

The authors argue that ethical judgment cannot be reduced to procedural compliance. Transplant teams themselves carry a broader responsibility to evaluate the relational dynamics that may undermine the voluntariness and authenticity of consent. Their three cases, involving candidates between 40 and 60 years old who voluntarily disclosed previously concealed intimate relationships during evaluation, illustrate how difficult this responsibility becomes when the information at stake is not medically relevant but is deeply morally significant.

In the first case, a recipient candidate disclosed to the transplant team a nearly decade-long extramarital relationship that had recently ended, but refused to tell the spouse who wished to donate a kidney to free them from lifelong dialysis and preserve the marriage. The team recognized that the donor’s offer rested on a presumption of mutual marital fidelity, and that knowledge of the affair might change the donor’s decision entirely. This created a direct conflict between the donor’s right to material information and the recipient’s right to privacy, particularly since the information had been shared in good faith. Some team members worried that the recipient’s decision to end the affair might itself have been implicitly coerced by the donor’s sacrificial gesture, raising questions about whether genuine informed consent was even possible under such emotional pressure. There was also concern that the donor might later use the gift as leverage to pressure reconciliation if the infidelity came to light. The team ultimately deferred, but did not prohibit, the transplant, hoping to give the recipient time for grief, reflection, or counselling. Notably, the recipient felt penalized for honesty, upset that candid voluntary disclosure had led to personal disadvantage.

The second case reversed the roles. Here, the donor disclosed a three-year extramarital affair that had preceded the recipient’s dialysis dependency, motivated by a desire to become a better spouse after witnessing the recipient’s fortitude during illness. The donor had ended the affair a full year before even raising the possibility of donation. The ethical concerns now centered on the recipient, whose consent would be obtained through ignorance of the donor’s infidelity. Yet the team reasoned that while emotionally significant, this information was not clearly material to the recipient’s evaluation of surgical risk, transplant prognosis, or expected clinical outcome. The recipient’s reason for accepting the kidney, escaping the burdens of dialysis, was independent of the donor’s past conduct. The team also acknowledged that some recipients might prefer not to know about spousal infidelity, exercising what ethicists call negative autonomy, and that preferences for disclosure vary widely across individuals. Crucially, they could not ascertain the recipient’s preference without revealing the truth itself. After deliberation, the team recommended proceeding, judging that deferral would not rewrite the marital history but could delay the recipient’s access to improved quality of life, potentially causing greater harm. The donation went ahead, and the donor made no subsequent disclosure of the affair.

The third case was the most complex. Both donor and recipient concealed an ongoing intimate relationship from their spouses and presented themselves as close friends. The donor claimed the offer was motivated by altruism, friendship, and compassion, while the recipient sought emancipation from dialysis. On the surface, the threshold for informed consent was met: both parties understood and accepted the risks and benefits, and both were voluntary in their decisions. Informed consent, the team noted, is owed to the donor and the recipient, not to their spouses, even if the spouses were misinformed about the nature of the relationship. But doubts emerged about whether the donor’s offer could be coerced as proof of devotion or driven by fear of abandonment, and whether the recipient might feel compelled to remain in the relationship because of the donation. The team also faced a deeper institutional bind: the transplant would be contingent on continued deception of both spouses, who would be placed in caregiving roles they had never agreed to, raising fairness concerns. The risk of exposure might not be high, but the reputational risk to a publicly accountable team was significant, particularly if marital breakdown or family conflict involving children followed. The team reached a unanimous decision on conditional deferral, giving the pair time to decide the future of their relationship before reconsidering the transplant. Both candidates, though disappointed, accepted the outcome.

What unites these cases is a common ethical question: should living-donor transplantation proceed when concealed intimate relationships materially affect the relational context in which donation occurs? The authors argue that spousal living donations are typically grounded in love, devotion, marital commitment, and preservation of the family unit. A decision to donate based on a material misunderstanding of the true nature of the donor-recipient relationship compromises autonomous decision-making. Because the donor alone assumes the physical risk, factors that undermine the donor’s ability to provide informed consent should carry greater ethical weight than those affecting the recipient. Privacy remains important, but it does not absolve transplant programs of their responsibility to safeguard the integrity of donor consent.

The authors also emphasize that conditional deferral, rather than outright prohibition, offers a proportionate response in many situations. Deferral provides time for relational instability to be addressed, for disclosure to be considered where appropriate, and for reliable post-operative support to be ensured. Since none of these cases involved urgent need for transplantation, and given that a TEC rejection effectively precludes transplantation anywhere in Singapore, deferral preserves the possibility of future transplantation once the identified concerns have been resolved. The authors frame this as proportional restraint rather than moral adjudication of private wrongdoing. They also point to Singapore’s Human Organ Transplant Regulations 2004, which statutorily require consideration of public interest and community values, concepts that may reasonably extend to preventing foreseeable harm to spouses, families, and marital relationships.

Ultimately, the authors conclude that transplant programs should not reject living kidney donation solely on the basis of moral discomfort with aspects of the donor-recipient relationship. But confidentiality and respect for autonomy alone are insufficient to justify proceeding when teams become aware of concealed extramarital relationships that materially affect the relational context of donation. Ignoring such relational realities risks reducing ethical oversight to procedural compliance rather than principled judgment. To the authors’ knowledge, this is the only known work discussing the impact of concealed intimate relationships in living-donor transplant, a gap they argue warrants further empirical and normative research to guide programs confronting these ethically complex situations.

Subject of Research: Ethical evaluation of concealed marital infidelity in living kidney donor and recipient consent

Article Title: Consent in the dark: Can living kidney donation proceed amid marital infidelity?

Article References: Lim, C., Voo, T. C., Chow, P. C.-L., & Krishna, L. K. R. (2026). Consent in the dark: Can living kidney donation proceed amid marital infidelity?. Transplant International, 39, Article 16580. https://doi.org/10.3389/ti.2026.16580

Image Credits: AI Generated

DOI: 10.3389/ti.2026.16580

Keywords: living kidney donation, informed consent, transplant ethics, marital infidelity, donor welfare, Transplant Ethics Committee, Singapore, Human Organ Transplant Act, institutional integrity, psychosocial evaluation, conditional deferral, public trust

Fibropapillomatosis is among the most consequential infectious diseases affecting marine turtles globally. It strikes green turtles most often, although cases have been documented in all sea turtle species, and its external tumors can grow around the eyes, neck, and flippers, impairing vision, movement, and feeding so severely that animals may starve or drown. The precise cause of the disease has never been fully resolved. Decades of research point to Scutavirus chelonidalpha5 as a key player, but the emergence and prevalence of fibropapillomatosis appear to be shaped by environmental conditions as well, particularly degraded water quality, eutrophication, and nutrient enrichment in coastal habitats.

Crucially, infection with the virus does not automatically mean illness. Numerous studies have found viral DNA in turtles that appear completely healthy, supporting the view that fibropapillomatosis is a multifactorial disease in which viral presence, host immunity, and environmental stressors interact to trigger tumor growth. This subtlety is what makes the Singapore findings so revealing: the virus was present not only in tumored animals but also in every apparently healthy individual sampled, suggesting that subclinical infections may be common in both species in the region.

The study began with two stranded green turtles found floating near East Coast Park and Lazarus Island in 2021 and 2022, both carrying multiple large external lesions on the neck and flippers. Internal examination revealed extensive pulmonary tumors that compromised lung integrity and buoyancy. Because veterinary diagnostic records were unavailable, the researchers classified the lesions based on gross morphology alone and describe them as suggestive of fibropapillomatosis rather than definitively diagnosed. The team then widened the net, analyzing whole-genome sequencing datasets from a total of four green turtles and four hawksbill turtles stranded or nesting in Singapore between 2020 and 2022, including individuals both with and without visible tumors.

The sequencing strategy was technically elegant. The team constructed Illumina TruSeq Nano paired-end libraries and sequenced them to roughly thirty-fold genome coverage on the HiSeq X platform. Because the viral genome is tiny, around 170 kilobases, compared with the roughly 2.1 gigabase turtle genome, viral sequences were expected to make up only a vanishingly small fraction of each dataset. To pull this signal out, the researchers used two complementary pipelines. The first, a reference-based approach using the BWA-MEM algorithm, aligned all quality-filtered reads against the reference viral genome, then filtered the results with SAMtools to retain only primary mapped read pairs. The second used Kraken2 metagenomic classification: host reads were subtracted, and the remaining reads were queried against the RefSeq viral database to count matches to the genus Scutavirus.

Both approaches told the same story. Viral sequences turned up in all eight genome datasets. After normalizing read counts to the smallest library size of roughly 223.8 million reads, reference-based viral counts ranged from about 30,869 to 98,326 reads, with the highest abundance found in a tumored green turtle from Lazarus Island. Kraken2 counts, between 178 and 488 normalized reads, mirrored the same pattern, and a Spearman’s rank correlation between the two methods was significant, indicating that the independent pipelines were capturing the same underlying viral signal. The concordance gives strong confidence that the detections are real rather than artifacts of any single analytical approach.

Perhaps the most striking result was what the statistics did not show. There was no significant difference in viral load between turtles with tumors and turtles without, and while green turtles carried somewhat higher counts than hawksbills, that difference also fell just short of significance with the small sample size. All four hawksbill turtles, none of which had visible tumors, still harbored detectable viral sequences. The authors caution that the sample sizes are small and unbalanced, and one green turtle muscle sample was excluded from statistical analysis because post-mortem contamination produced an unreliable taxonomic profile. Even so, the pattern is consistent with studies elsewhere showing that visual surveys based on tumors alone likely underestimate true infection rates.

That finding matters for conservation because turtles without symptoms may act as cryptic carriers, quietly maintaining the virus within populations. Viral infection can remain latent, and loads may drop below detection thresholds depending on tissue type, infection stage, and species, further limiting the reliability of external examinations. The researchers argue that host whole-genome sequencing, by enabling unbiased viral detection in both sick and healthy animals, offers a sensitive complement to existing viral, histological, and environmental DNA monitoring methods. Combined approaches of this kind could catch infections long before tumors appear.

Singapore’s urban coastline makes the discovery especially poignant. Land reclamation, urban runoff, and pollution have drastically altered the island nation’s natural shores, and pollution is known to weaken immune function in marine organisms, potentially raising susceptibility to diseases like fibropapillomatosis. Globally, higher disease prevalence has been linked to eutrophic, polluted coastal habitats. The study’s authors are careful to note that environmental parameters were not measured in this work, so no direct link between pollution and viral presence can be drawn from the data. Still, the hypothesis that heavily impacted coastal ecosystems elevate disease risk fits the emerging picture that fibropapillomatosis reflects an interaction among viral exposure, host immune status, microbiome composition, and environmental stress rather than pathogen presence alone.

There are also broader geographic implications. Southeast Asia has long been a surveillance gap for this disease. The earliest known regional record dates to 1958, when fibropapillomatosis was reported in nesting green turtles at Malaysia’s Sarawak Turtle Islands, and subsequent studies have documented cases in Indonesia and Taiwan along with molecular evidence of the virus in green, hawksbill, and olive ridley turtles in Borneo. The Singapore data now fill in a missing piece of that map in one of the most heavily urbanized marine environments on Earth. The team calls for comprehensive health assessments across Singapore and the wider region, integrating water quality and pollutant monitoring with molecular and clinical surveillance, alongside more systematic sampling across species, life stages, and tissue types, and histopathological confirmation of lesions in future work. If the virus proves to be a sentinel of cumulative environmental stress, then tracking it genomics-first could benefit not just the turtles but the ecosystems they inhabit.

Subject of Research: Detection of Scutavirus chelonidalpha5, the virus linked to fibropapillomatosis, in green and hawksbill turtles from Singapore using host whole-genome sequencing

Article Title: Host whole-genome sequencing reveals Scutavirus chelonidalpha5 infection in sea turtles from Singapore

Article References: Tanabe, L. K., Espinosa, A. G., Tiong, R. H. Y., & Kim, H. L. (2026). Host whole-genome sequencing reveals Scutavirus chelonidalpha5 infection in sea turtles from Singapore. Frontiers in Amphibian and Reptile Science, 4, Article 1814588. https://doi.org/10.3389/famrs.2026.1814588

Image Credits: AI Generated

DOI: 10.3389/famrs.2026.1814588

Keywords: sea turtles, Scutavirus chelonidalpha5, fibropapillomatosis, herpesvirus, whole-genome sequencing, metagenomics, Singapore, green turtle, hawksbill turtle, marine conservation, urbanization, wildlife disease

The new study, published in Frontiers in Medical Technology, explored whether three-dimensional facial imaging could serve as a source of digital biomarkers in rare diseases, with a particular focus on hereditary angioedema, or HAE. HAE is a genetic disorder caused by a defect in the SERPING1 protein, which regulates inflammation and fluid balance in blood vessels. The result is intermittent swelling of soft tissues, most often around the eyes and mouth. In most cases the swelling is painful and disfiguring, but when it involves the airways it can become life-threatening within hours, demanding immediate medical care.

The problem, the researchers explain, is that HAE is frequently missed or diagnosed late, and even after a diagnosis is secured, there is no objective way to measure a flare-up. Treatment decisions rest on subjective patient reports and clinical impressions, which can delay therapy and heighten anxiety. The team, led by Saumya Jamuar of KK Women’s and Children’s Hospital in Singapore and Gareth Baynam of Perth Children’s Hospital in Australia, set out to determine whether the face itself could provide measurable, quantifiable evidence of disease activity.

The study, conducted over four years and eight months across three Singapore hospitals, had two complementary components. In the quantitative arm, 20 participants of Chinese genetic ancestry with rare diseases characterized by facial swelling or asymmetry were photographed with a Vectra M3 3D camera. The cohort included individuals with mucopolysaccharidosis, Noonan syndrome, incontinentia pigmenti, velocardiofacial syndrome, and achondroplasia, as well as five with HAE. Their facial scans were then processed with Cliniface, an artificial intelligence-powered software platform developed in Western Australia, which extracts facial landmarks and 58 distinct measurements from each image.

The analytical approach was deliberately rigorous. From the 58 base measurements, the team generated 108 separate measurement variables, each expressed as a z-score comparing the affected participant to a regressed growth curve derived from a demographically matched, disease-free reference population spanning ages zero to 70. Outliers beyond three standard deviations were removed before regression, and the resulting z-scores were tested for normality using Monte Carlo hypothesis testing. Two-tailed t-tests were then applied, and because so many variables were tested simultaneously, the team applied the Holm-Bonferroni correction to control the family-wise error rate, a conservative method that does not assume the measurements are statistically independent.

After this gauntlet of statistical filtering, a single measurement survived: the Outer Canthal, Nasal Angle, which retained a corrected p-value of 0.01, indicating a significant deviation from the ethnically matched norm. Ten other measurements, including several related to facial asymmetry, showed uncorrected p-values below 0.05 but did not survive the multiple-comparison adjustment. The researchers caution that the small sample size and the heterogeneity of the test cohort mean these findings require independent replication. Still, the result suggests that 3D facial imaging may be capable of detecting subtle, measurable differences in people who experience facial swelling even between overt episodes.

The qualitative arm of the study provided the more visually striking findings. Two adults with HAE were photographed serially over extended periods, including during acute flare-ups. The first participant, a man of Malay genetic ancestry, was imaged at seven time points over 687 days, including immediately after a facial oedema flare. Procrustes analysis of his scans revealed asymmetric periorbital swelling, with an increase of more than three millimeters around one eye following the flare. The swelling diminished over subsequent visits, and a later scan taken during a period when the participant had stopped taking his medication showed residual swelling that had not fully subsided, hinting that the technique might even detect subclinical exacerbations or treatment non-compliance.

The second participant, a woman of Indian genetic ancestry, was photographed twice, 261 days apart, with the first image captured immediately after an acute episode. Her scans showed asymmetric periorbital swelling, more pronounced on one side, along with asymmetric swelling of the cheeks and lower jaw. The consistency of these findings between two unrelated individuals, each showing swelling and asymmetry during flares, even on different sides of the face, led the team to propose periorbital swelling and asymmetry as a working hypothesis for a digital biomarker in HAE. Notably, they point out that purely landmark-based approaches that ignore symmetry could miss critical indicators of disease activity.

The researchers are careful to frame their conclusions as preliminary. The quantitative cohort contained only five individuals with HAE, the qualitative analysis was limited to two participants, and the reference growth curves did not account for sex differences. Singapore’s small population and the rarity of these conditions made a larger cohort impractical, but the team acknowledges that broader studies across different genetic ancestries, ages, and sexes will be essential before the approach can be validated for clinical use. They also note that while digital phenotyping’s diagnostic capabilities may be limited, its ability to identify digital biomarkers could still facilitate disease monitoring even when it cannot replace clinical diagnosis.

If validated, the implications extend well beyond HAE. Rare disease clinical trials are chronically hampered by small, fragmented patient populations, subjective outcome measures, and symptoms that fluctuate over time, contributing to higher failure rates than in trials for common conditions. An objective, non-invasive biomarker derived from a simple facial photograph could provide the precise, repeatable endpoints that such trials desperately need. The team hopes that ongoing data collection from participants of different ancestries and disease conditions will identify additional digital biomarkers, moving the field closer to a future where a face scan helps clinicians detect, monitor, and treat rare diseases with greater confidence and speed.

Subject of Research: Utility of 3D facial analysis as a biomarker in rare diseases exploration with hereditary angioedema

Article Title: Utility of 3D facial analysis as a biomarker in rare diseases exploration with hereditary angioedema

Article References: Jamuar, S., Palmer, R., Lee, H. Y., Chia, F. L.-A., Goh, C. B., Lee, S., Helmholz, P., Chan, S., & Baynam, G. (2026). Utility of 3D facial analysis as a biomarker in rare diseases exploration with hereditary angioedema. Frontiers in Medical Technology, 8, Article 1857918. https://doi.org/10.3389/fmedt.2026.1857918

Image Credits: AI Generated

DOI: 10.3389/fmedt.2026.1857918

Keywords: 3D facial imaging, digital biomarkers, hereditary angioedema, rare diseases, digital phenotyping, diagnostic odyssey, Cliniface, periorbital swelling, precision medicine, SERPING1, clinical trials, Singapore